Ionis Pharmaceuticals (IONS) investor relations material

Executive summary

• Q3 revenue was $242.7M and nine-month revenue was $756.8M; excluding the prior-year $280M sapablursen payment, revenue grew 55% and 64% YoY, respectively.

• Commercial revenue exceeded R&D revenue in Q3, with DAWNZERA leading product growth; TRYNGOLZA’s slower sHTG launch prompted lower 2026 sales guidance.

• Portfolio and pipeline advances included ZANVASTRO and HIBSAGO approvals and positive Phase 3 results for sefaxersen and ulefnersen; pelacarsen and eplontersen Phase 3 programs had setbacks.

Financial highlights

• Q3 revenue was $242.7M versus $156.7M; nine-month revenue was $756.8M versus $740.4M.

• Q3 commercial revenue was $136.2M versus $115.6M, while R&D revenue was $106.5M versus $41.1M; nine-month commercial revenue was $363M, up 23% YoY.

• Q3 product sales were $36.8M for DAWNZERA, $9.3M for TRYNGOLZA and $2.2M for ZANVASTRO; nine-month sales were $79M and $41M for DAWNZERA and TRYNGOLZA, respectively.

• Nine-month GAAP operating expenses were $1.107B and non-GAAP expenses were $975M; Q3 net loss narrowed to $110.0M from $128.6M.

Outlook and guidance

• 2026 total revenue guidance remained $875M–$900M, non-GAAP operating loss guidance $425M–$475M, and year-end cash guidance above $1.6B.

• TRYNGOLZA 2026 net product sales guidance was reduced to ~$50M from $100M–$110M; DAWNZERA guidance remained $110M–$120M.

• Operating expenses were expected to grow at a low-teens percentage rate; R&D expense was expected near the prior-year level.

• Sustained positive cash flow break-even timing shifted from 2028 to 2029, reflecting the TRYNGOLZA ramp and Phase 3 setbacks.

• 2027 guidance was expected at the February year-end earnings call; further TRYNGOLZA payer access was anticipated through 2027.